| Exclusion Criteria: | 1) Active brain metastases; brain metastases allowed provided they have been treated with surgery and/or radiation therapy and show no evidence of progression on cerebral CT or MRI scan 2 months following surgery and/or radiation therapy
2) Concurrent severe and/or uncontrolled medical disease (eg, uncontrolled diabetes, Class III or IV congestive cardiac failure as defined by the New York Heart Association, myocardial infarction within 6 months before enrollment) that could compromise participation in the study
3) Uncontrolled severe hypertension (>= 140/90 despite controlling medication)
4) Documented history of human immunodeficiency virus infection
5) Documented history of viral chronic hepatitis
6) Received biologic, small molecule, immunotherapy, chemotherapy, radiotherapy or other agents to treat renal cancer within 28 days before enrollment
7) Treated previously with any c-Met or HGF targeted therapy
8) Concurrent or prior (within 7 days before enrollment) anticoagulation therapy, unless: a) Subject has an INR value of between 2.0 and 3.0 while on a stable dose of a coumarin-type anticoagulant for at least 30 days prior to enrollment, and b) Subject does not have a history of clinically significant bleeding or bruising while on anticoagulants
9) Concurrent use of hormones or other chemotherapeutic agents except for steroids given for adrenal failure and hormones administered for nondisease- related conditions (eg, insulin for diabetes); except for non-cancer reasons.
10) Concurrent palliative or therapeutic radiation therapy
11) Currently enrolled in or has not yet completed at least 30 days since ending other investigational device or therapy, or subject is receiving other investigational agent(s)
12) Active infection requiring treatment within 1 week before enrollment
13) Undergone major surgery within 4 weeks before enrollment or recovering from prior surgery
14) Past or current history of another neoplasm, except for curatively treated nonmelanoma skin cancer, carcinoma in situ of the cervix and other primary solid cancer with no known active disease present and no curative treatment administered for the last 3 years
15) Known allergy or sensitivity to any of the excipients in the investigational product to be administered
16) Pregnant or is breast feeding
17) Not consenting to use adequate contraceptive precautions during the course of the study and for 6 months after the last administration of investigational product - female subjects who are post menopausal (no menstrual period for a minimum of 12 months at study entry) or documented surgically sterile will not be bound to this requirement
18) Previously treated with AMG 102
19) Previously enrolled into this study
20) Will not be available for follow-up assessments
21) Has other disorders that compromises the ability of the subject to give written informed consent and/or comply with study procedures
22) Unable to begin protocol specified treatment within 3 days after enrollment |